Anita Turk, MD, details her biggest takeaways from the 2025 ASCO Annual Meeting in gastrointestinal cancers. Anita Turk, MD, medical oncologist at IU Health, discusses her biggest takeaways in the ...

Gynecologic clear cell cancers are aggressive malignant neoplasms with low response rates to chemotherapy. Among patients ...

BMY’s robust launch portfolio, resilient free cash flow, and above-consensus growth outlook position it for outsized returns ...

Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer ...

Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The stock has also ...

All attendees shared a vested interest in the rapidly evolving cancer treatment landscape. Nowhere was the vastness of that ...

Operator: Good afternoon, and welcome to the Aethlon Medical Fourth Quarter Fiscal 2025 Earnings and Corporate Update ...

Motor City Mile Open Water Swim Makes Waves to Fight Cancer, all proceeds go to University of Michigan cancer center.

Bonilla, MD, MSEd, discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the 2025 ASCO Annual Meeting.

BMS’ Opdivo, used in combination with chemotherapy, is now allowed in advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancers only among patients whose tumors ...

Oral cancer, which includes malignancies affecting the lips, tongue, gums, cheeks, and floor of the mouth, represents a ...

Bristol-Myers Squibb faces patent losses and growth headwinds despite pipeline gains, debt cuts, and dividends. Read why BMY ...